NovaBridge net loss widens to $37.9 million in FY26 first half; R&D expenses more than doubled to $14.3 million - NBP News | RalliesNovaBridge net loss widens to $37.9 million in FY26 first half; R&D expenses more than doubled to $14.3 million
N
NBP• Pipeline update
- Givastomig Phase 2 began in February; Fast Track was secured in June, with Phase 3 initiation targeted as early as year-end 2026.
- VIS-101 Phase 2b is expected to start in H2 2026; a global Phase 3 is planned for 2027, following positive Phase 2a data.
First-half loss widens as spending increases
- NovaBridge posted a GAAP net loss of $37.9 million; loss per share widened to $0.14.
- R&D expenses climbed to $14.3 million; administrative expenses rose to $26.4 million.
- Cash, cash equivalents, short-term investments, and equity investment totaled $215.9 million as of June 30, 2026.
•
